Between crime and colony: Interrogating (im)mobilities aboard the convict ship

Recent literature in carceral geography has attended to the importance of mobilities in interrogating the experience and control of spaces of imprisonment, detention and confinement. Scholars have explored the paradoxical nature of incarcerated experience as individuals oscillate between moments of fixity and motion as they are transported to/from carceral environments. This paper draws upon the convict ship – an example yet to gain attention within these emerging discussions – which is both an exemplar of this paradox and a lens through which to complicate understandings of carceral (im)mobilities. The ship is a space of macro-movement from point A to B, whilst simultaneously a site of apparent confinement for those aboard who are unable to move beyond its physical parameters. Yet, we contend that all manner of mobilities permeate the internal space of the ship. Accordingly, we challenge the binary thinking that separates moments of fixity from motion and explore the constituent parts that shape movement. In paying attention to movements in motion on the ship, we argue that studies of carceral mobility must attend to both methods of moving in the space between points A and B; as micro, embodied and intimate (im)mobilities are also played out within large-scale regimes of movement

Performance of eight serum cytokine/chemokine biomarkers in discriminating between active and latent tuberculosis infection in Ghana

IntroductionThe existing Interferon γ release assay (IGRA) tests for TB infection, lacks utility in discriminating between active TB (ATB) and latent TB infection (LTBI). This study evaluated the potential of eight serum cytokines/chemokines in differentiating LTBI from ATB and as a surrogate marker for TB treatment response.MethodsWe quantified and compared the serum levels of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-12p70, IL-17A, Granzyme B) and anti-inflammatory cytokines (IL-10, IL-6, IL-4) among LTBI, ATB, and healthy controls using the Human Magnetic Luminex™ 200 system. Serum cytokine/chemokine levels were also assessed at four timepoints before and during TB treatment.ResultsAmong ATB cases, there were twice as many males (69%) as females (30%), with infectivity spanning a wide age range. IFN-γ, IL-6, IL-10, IL-4, and IL-17A levels were higher in LTBI compared to ATB. IL-12p70 was found to be a good discriminant between ATB and LTBI (21-fold increase in ATB compared to LTBI, p < 0.05) but it did not have a good predictive potential for treatment (follow up). The predictive potential of TNF-α, IL-6, IL-10, IFN-γ, IL-4, IL-17A, Granzyme B and IL-12p70 to differentiate between ATB and LTBI using AUROC was 57%, 98 %, 91%, 100%, 100%, 97%, 66% and 100% respectively.DiscussionThese findings confirm reports from other studies in different settings that LTBI and ATB express differential cytokine profiles that can be exploited as diagnostic biomarkers. Of note, the quantitative estimation of IL-12p70 may serve as a valuable marker for monitoring disease progression and treatment success in tuberculosis

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19. Methods: Patients admitted with COVID-19 pneumonia to 107 UK hospitals were randomly assigned (1:1) to either usual care alone or usual care plus a single 1 g infusion of sotrovimab, using web-based unstratified randomisation. Participants were eligible if they were aged at least 18 years, or aged 12–17 years if weighing at least 40kg, and had confirmed COVID-19 pneumonia with no medical history that would put them at significant risk if they participated in the trial. Participants were retrospectively categorised as having a high antigen level if baseline serum SARS-CoV-2 nucleocapsid antigen was above the median concentration (the prespecified primary efficacy population), otherwise they were categorised as having a low antigen level. The primary outcome was 28-day mortality assessed by intention to treat. Safety outcomes were assessed among all participants, regardless of antigen level. Recruitment closed on March 31, 2024, when funding ended. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: From Jan 4, 2022, to March 19, 2024, 1723 patients were enrolled in the RECOVERY sotrovimab comparison. Of these, 828 (48%) were assigned to usual care plus sotrovimab and 895 (52%) were assigned to usual care only. Mean patient age was 70·7 years (SD 14·8) and 1033 (60%) were male. 720 (42%) patients were classified as having a high antigen level, 717 (42%) as having a low antigen level, and 286 (17%) had unknown antigen status. 1389 (81%) patients were vaccinated, 1179 (82%) of 1438 patients with known serostatus had anti-spike antibodies at randomisation, and 1021 (>99%) of 1026 patients with sequenced samples were infected with omicron variants. Among patients with a high antigen level, 82 (23%) of 355 assigned to sotrovimab versus 106 (29%) of 365 assigned usual care died within 28 days (rate ratio 0·75, 95% CI 0·56–0·99; p=0·046). In an analysis of all randomly assigned patients (regardless of antigen status), 177 (21%) of 828 patients assigned to sotrovimab versus 201 (22%) of 895 assigned to usual care died within 28 days (0·95, 0·77–1·16; p=0·60). Infusion reactions were recorded in 12 (2%) of 781 patients receiving sotrovimab. We found no difference between groups in any other safety outcome. Interpretation: In patients admitted to hospital with COVID-19 pneumonia, sotrovimab was associated with reduced mortality in the primary analysis population who had a high serum SARS-CoV-2 antigen concentration at baseline, but not in the overall population. Treatment options for patients admitted to hospital are limited, and mortality in those receiving current standard of care was high. The emergence of high-level resistance to sotrovimab among subsequent SARS-CoV-2 variants restricts its current usefulness, but these results indicate that targeted neutralising antibody therapy could potentially still benefit some patients admitted to hospital who are at high risk of death in an era of widespread vaccination and omicron infection. Funding: UK Research and Innovation (Medical Research Council) and National Institute for Health and Care Research

Reading Postemancipation In/Security: Negotiations of Everyday Freedom

This essay examines in/securities through a central focus on strategies for securing livelihoods after emancipation. While the postemancipation period in the Caribbean was marked by clamorous debate about the region’s economic future, this essay is concerned with the quieter practices that shaped the texture of freedom. An engagement with travel narratives, specifically attentive to reading against the grain of elite mobilities, is proposed as a means through which to reveal the everyday negotiation of livelihoods. Offering the market as a case study, the essay argues that everyday negotiations of economic insecurity rested on mobile strategies and that the mobilization of such strategies took on a new significance with the rise of tourism in the decades after emancipation

Screening and Panel Discussion on the work of Angela Davis, Free Angela and Other Political Prisoners

The screening and panel have been organised to coincide with Angela Davis receiving an honorary degree from Goldsmiths on December 14th 2013. We will be recognising and celebrating the work of Angela Davis with a specific focus on her contributions to Black feminism. The panel with Sara Ahmed (Media and Communications), Joan Anim-Addo (English Language and Literature/Centre for Caribbean Studies), Claudia Bernard (Social, Therapeutic and Community Studies), Heidi Mirza (Sociology), Nirmal Puwar (Sociology) and Sunera Thobani (UBC, Vancouver). This event continues a series on ‘feminist and queer of colour scholarship and activism’ that began in 2011, with a day focusing on the work of Audre Lorde